IBDEI12X ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,18017,1,3,0)
 ;;=3^86485
 ;;^UTILITY(U,$J,358.3,18018,0)
 ;;=86486^^93^897^4^^^^1
 ;;^UTILITY(U,$J,358.3,18018,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,18018,1,2,0)
 ;;=2^MUMPS
 ;;^UTILITY(U,$J,358.3,18018,1,3,0)
 ;;=3^86486
 ;;^UTILITY(U,$J,358.3,18019,0)
 ;;=86580^^93^897^5^^^^1
 ;;^UTILITY(U,$J,358.3,18019,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,18019,1,2,0)
 ;;=2^TB
 ;;^UTILITY(U,$J,358.3,18019,1,3,0)
 ;;=3^86580
 ;;^UTILITY(U,$J,358.3,18020,0)
 ;;=95024^^93^897^3^^^^1
 ;;^UTILITY(U,$J,358.3,18020,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,18020,1,2,0)
 ;;=2^INTRADERMALS (EACH)
 ;;^UTILITY(U,$J,358.3,18020,1,3,0)
 ;;=3^95024
 ;;^UTILITY(U,$J,358.3,18021,0)
 ;;=86510^^93^897^2^^^^1
 ;;^UTILITY(U,$J,358.3,18021,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,18021,1,2,0)
 ;;=2^HISTOPLASMOSIS
 ;;^UTILITY(U,$J,358.3,18021,1,3,0)
 ;;=3^86510
 ;;^UTILITY(U,$J,358.3,18022,0)
 ;;=99395^^93^898^1^^^^1
 ;;^UTILITY(U,$J,358.3,18022,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,18022,1,2,0)
 ;;=2^PREVENTIVE MED,EST PT 18-39
 ;;^UTILITY(U,$J,358.3,18022,1,3,0)
 ;;=3^99395
 ;;^UTILITY(U,$J,358.3,18023,0)
 ;;=99396^^93^898^2^^^^1
 ;;^UTILITY(U,$J,358.3,18023,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,18023,1,2,0)
 ;;=2^PREVENTIVE MED,EST PT 40-64
 ;;^UTILITY(U,$J,358.3,18023,1,3,0)
 ;;=3^99396
 ;;^UTILITY(U,$J,358.3,18024,0)
 ;;=99397^^93^898^3^^^^1
 ;;^UTILITY(U,$J,358.3,18024,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,18024,1,2,0)
 ;;=2^PREVENTIVE MED,EST PT > 64
 ;;^UTILITY(U,$J,358.3,18024,1,3,0)
 ;;=3^99397
 ;;^UTILITY(U,$J,358.3,18025,0)
 ;;=99385^^93^899^1^^^^1
 ;;^UTILITY(U,$J,358.3,18025,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,18025,1,2,0)
 ;;=2^PREVENTIVE MED,NEW PT 18-39
 ;;^UTILITY(U,$J,358.3,18025,1,3,0)
 ;;=3^99385
 ;;^UTILITY(U,$J,358.3,18026,0)
 ;;=99386^^93^899^2^^^^1
 ;;^UTILITY(U,$J,358.3,18026,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,18026,1,2,0)
 ;;=2^PREVENTIVE MED,NEW PT 40-64
 ;;^UTILITY(U,$J,358.3,18026,1,3,0)
 ;;=3^99386
 ;;^UTILITY(U,$J,358.3,18027,0)
 ;;=99387^^93^899^3^^^^1
 ;;^UTILITY(U,$J,358.3,18027,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,18027,1,2,0)
 ;;=2^PREVENTIVE MED,NEW PT > 64
 ;;^UTILITY(U,$J,358.3,18027,1,3,0)
 ;;=3^99387
 ;;^UTILITY(U,$J,358.3,18028,0)
 ;;=B18.2^^94^900^26
 ;;^UTILITY(U,$J,358.3,18028,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18028,1,3,0)
 ;;=3^Hepatitis C,Chr
 ;;^UTILITY(U,$J,358.3,18028,1,4,0)
 ;;=4^B18.2
 ;;^UTILITY(U,$J,358.3,18028,2)
 ;;=^5000548
 ;;^UTILITY(U,$J,358.3,18029,0)
 ;;=C44.99^^94^900^50
 ;;^UTILITY(U,$J,358.3,18029,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18029,1,3,0)
 ;;=3^Skin Cancer,Unspec
 ;;^UTILITY(U,$J,358.3,18029,1,4,0)
 ;;=4^C44.99
 ;;^UTILITY(U,$J,358.3,18029,2)
 ;;=^5001094
 ;;^UTILITY(U,$J,358.3,18030,0)
 ;;=E11.9^^94^900^15
 ;;^UTILITY(U,$J,358.3,18030,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18030,1,3,0)
 ;;=3^Diabetes Type 2
 ;;^UTILITY(U,$J,358.3,18030,1,4,0)
 ;;=4^E11.9
 ;;^UTILITY(U,$J,358.3,18030,2)
 ;;=^5002666
 ;;^UTILITY(U,$J,358.3,18031,0)
 ;;=E11.40^^94^900^16
 ;;^UTILITY(U,$J,358.3,18031,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18031,1,3,0)
 ;;=3^Diabetes Type 2 w/ Neuropathy
 ;;^UTILITY(U,$J,358.3,18031,1,4,0)
 ;;=4^E11.40
 ;;^UTILITY(U,$J,358.3,18031,2)
 ;;=^5002644
 ;;^UTILITY(U,$J,358.3,18032,0)
 ;;=E78.2^^94^900^27
 ;;^UTILITY(U,$J,358.3,18032,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18032,1,3,0)
 ;;=3^Hyperlipidemia,Mixed
 ;;^UTILITY(U,$J,358.3,18032,1,4,0)
 ;;=4^E78.2
 ;;^UTILITY(U,$J,358.3,18032,2)
 ;;=^78424
 ;;^UTILITY(U,$J,358.3,18033,0)
 ;;=E78.5^^94^900^28
